• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase I toxicity study of human rDNA interferon in patients with solid tumours.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Wagstaff, John
    Chadwick, G
    Howell, Anthony
    Thatcher, Nick
    Scarffe, J Howard
    Crowther, Derek
    Affiliation
    Cancer Research Campaign Department of Medical Oncology, University of Manchester, Christie Hospital and Holt Radium Institute, Wilmslow Road, M20 9BX Manchester, England.
    Issue Date
    1984
    
    Metadata
    Show full item record
    Abstract
    This study was designed to evaluate the clinical tolerance to multiple IM injections of rDNA-produced human alpha-2 interferon (IFN) (Schering-Plough 30500) in patients with solid tumours. IFN was administered in escalating IM doses in separate groups of patients daily for 14 days and then twice weekly for a further 10 weeks. The dosage levels were 1, 3, 10, and 30 million U/injection. Subjective toxicity could be divided into two types, acute and chronic. The acute reactions took the form of an influenza-like syndrome consisting in chills, rigors, headache, tremor, nausea, vomiting, and myalgia. These symptoms were dose-related but tachyphylaxis developed with continued dosing. The chronic toxicity consisted of malaise, lethargy, fatigue, anorexia, and confusion. These symptoms were not so dose-dependent and tended to become more severe with prolonged treatment. Objective toxicity consisted of myelosuppression and liver dysfunction. Granulocyte counts below 1.0 X 10(9)/l were seen in three patients at the 30-million-U level, with platelet counts less than 100 X 10(9)/l in two of these. Elevation of the liver enzymes were seen in all five patients treated at 30 million U, but returned to normal after 1 week without IFN in all but one patient. A tolerable dose (IM) for phase II/III studies lies between 3 and 10 million U for daily scheduling and between 10 and 30 million U for twice-weekly injections.
    Citation
    A phase I toxicity study of human rDNA interferon in patients with solid tumours. 1984, 13 (2):100-5 Cancer Chemother Pharmacol
    Journal
    Cancer Chemotherapy and Pharmacology
    URI
    http://hdl.handle.net/10541/108055
    DOI
    10.1007/BF00257123
    PubMed ID
    6467493
    Type
    Article
    Language
    en
    ISSN
    0344-5704
    ae974a485f413a2113503eed53cd6c53
    10.1007/BF00257123
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    • Authors: Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M
    • Issue date: 1999 Dec
    • Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    • Authors: Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S
    • Issue date: 1983
    • Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    • Authors: Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M
    • Issue date: 2000 Sep
    • Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
    • Authors: Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU
    • Issue date: 1986 Nov
    • A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
    • Authors: Sriskandan K, Garner P, Watkinson J, Pettingale KW, Brinkley D, Calman FM, Tee DE
    • Issue date: 1986
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.